Information Request Letter, December 31, 2012 - BAT


Our Reference:  STN 125462/0

Cangene Corporation
Attention:  Mr. Terry Kraynyk
December 31, 2012
Sent by email

Dear Mr. Kraynyk:

We are reviewing your biologics license application for Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) (Equine) submitted on September 20, 2012 for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin (BoNT) serotypes A, B, C, D, E, F or G.  We determined that the following information is necessary to continue our review:

Clinical:

1.The files submitted to BLA 125262 from CDC expanded access program IND 6750 include HHS/ASPR/BARDA semiannual summary reports up to report #3. These HHS/ASPR/BARDA reports cover from 15-Jan-2008 through 31-Dec-2011.  However, the information provided is inadequate to evaluate the safety of NP-018 in the target population, particularly in children. Therefore, we request additional clinical safety data available up until the present time.  Please provide HHS/ASPR/BARDA report #4 dated 27-July-2012.  Also, please provide other data of interest which have occurred between report #3 and the present, including deaths, serious adverse events, severe adverse events, and episodes of anaphylaxis or serum sickness.  Please also provide summaries and detailed narratives of all pediatric data to the present, including all pediatric dosing     information, with infant data presented both as included and separate collections.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission. 

Please submit your response to this information request as an amendment to this file by January 18, 2013 referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

If you have any questions, please contact me at (301) 827-6174.

Sincerely,

Nannette Cagungun, MS, PD, RAC 
Regulatory Project Manager 
OBRR/CBER/FDA, HFM-380 
1401 Rockville Pike Rockville, MD 20852-1448 
Tel: (301) 827 6174 
Fax: (301) 827 2857 
Email: nannette.cagungun@fda.hhs.gov 
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.
